Search
forResearch 10 of 1000+
- Discovery of a Novel Non-invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic Alopecia
- PROTAC Degraders of Androgen Receptor‐Integrated Dissolving Microneedles for Androgenetic Alopecia and Recrudescence Treatment via Single Topical Administration
- Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- 1116 Novel androgen receptor degrader for androgenetic alopecia (AGA) application
- Androgen receptor modulators: a review of recent patents and reports (2012-2018)
- Evolving CRBN ligands enhance the drug-like properties of protein degraders
- Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
- Advancing Design Strategy of PROTACs for Cancer Therapy
Learn 1
Community 3 of 58
- Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
- bro where tf is GT20029, Q1 2024 is over already
- PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance